These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

479 related articles for article (PubMed ID: 31191001)

  • 21. Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years.
    Kaye SB
    Ann Oncol; 2016 Apr; 27 Suppl 1(Suppl 1):i1-i3. PubMed ID: 27141062
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PARP inhibitors as potential therapeutic agents for various cancers: focus on niraparib and its first global approval for maintenance therapy of gynecologic cancers.
    Sisay M; Edessa D
    Gynecol Oncol Res Pract; 2017; 4():18. PubMed ID: 29214031
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [From poly(ADP-ribose) discovery to PARP inhibitors in cancer therapy].
    Schreiber V; Illuzzi G; Héberlé E; Dantzer F
    Bull Cancer; 2015 Oct; 102(10):863-73. PubMed ID: 26384693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Patient Counseling and Management of Symptoms During Olaparib Therapy for Recurrent Ovarian Cancer.
    Moore KN; Monk BJ
    Oncologist; 2016 Aug; 21(8):954-63. PubMed ID: 27256873
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer.
    Ledermann JA; Pujade-Lauraine E
    Ther Adv Med Oncol; 2019; 11():1758835919849753. PubMed ID: 31205507
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Latest clinical evidence and further development of PARP inhibitors in ovarian cancer.
    Mirza MR; Pignata S; Ledermann JA
    Ann Oncol; 2018 Jun; 29(6):1366-1376. PubMed ID: 29750420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARP inhibitors: a tsunami of indications in different malignancies.
    Haddad G; Saadé MC; Eid R; Haddad FG; Kourie HR
    Pharmacogenomics; 2020 Feb; 21(3):221-230. PubMed ID: 31967513
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pamiparib for germline BRCA mutation-associated recurrent advanced ovarian, fallopian tube or primary peritoneal cancer.
    Skrzypczyk-Ostaszewicz A
    Drugs Today (Barc); 2022 Jun; 58(6):299-309. PubMed ID: 35670707
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Role of PARP Inhibitors in the Treatment of Gynecologic Malignancies.
    Reinbolt RE; Hays JL
    Front Oncol; 2013 Oct; 3():237. PubMed ID: 24098868
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The poly (ADP ribose) polymerase inhibitor niraparib: Management of toxicities.
    Moore KN; Mirza MR; Matulonis UA
    Gynecol Oncol; 2018 Apr; 149(1):214-220. PubMed ID: 29397193
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Update on Poly ADP-Ribose Polymerase Inhibitors in Ovarian Cancer With Non-BRCA Mutations.
    Xu Q; Li Z
    Front Pharmacol; 2021; 12():743073. PubMed ID: 34912215
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Emerging treatment options for ovarian cancer: focus on rucaparib.
    Mariappan L; Jiang XY; Jackson J; Drew Y
    Int J Womens Health; 2017; 9():913-924. PubMed ID: 29290694
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel poly-ADP-ribose polymerase inhibitor combination strategies in ovarian cancer.
    McCann KE
    Curr Opin Obstet Gynecol; 2018 Feb; 30(1):7-16. PubMed ID: 29251678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Cancer therapy by PARP inhibitors].
    Seimiya H
    Nihon Rinsho; 2015 Aug; 73(8):1330-5. PubMed ID: 26281686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Development of poly(ADP-ribose) polymerase inhibitors in the treatment of BRCA-mutated breast cancer.
    Sulai NH; Tan AR
    Clin Adv Hematol Oncol; 2018 Jul; 16(7):491-501. PubMed ID: 30067621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PARP Inhibitors and the Evolving Landscape of Ovarian Cancer Management: A Review.
    Cook SA; Tinker AV
    BioDrugs; 2019 Jun; 33(3):255-273. PubMed ID: 30895466
    [TBL] [Abstract][Full Text] [Related]  

  • 37. BRCA Status Does Not Predict Synergism of a Carboplatin and Olaparib Combination in High-Grade Serous Ovarian Cancer Cell Lines.
    Shen YT; Evans JC; Zafarana G; Allen C; Piquette-Miller M
    Mol Pharm; 2018 Jul; 15(7):2742-2753. PubMed ID: 29750868
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
    Zhu H; Wei M; Xu J; Hua J; Liang C; Meng Q; Zhang Y; Liu J; Zhang B; Yu X; Shi S
    Mol Cancer; 2020 Mar; 19(1):49. PubMed ID: 32122376
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rucaparib: a novel PARP inhibitor for
    Colombo I; Lheureux S; Oza AM
    Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
    Hennes ER; Dow-Hillgartner EN; Bergsbaken JJ; Piccolo JK
    J Oncol Pharm Pract; 2020 Apr; 26(3):718-729. PubMed ID: 31902284
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.